Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2022, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 3, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypertrophic Cardiomyopathy - Overview
Hypertrophic Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypertrophic Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
Algomedix Inc
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
C&C BioPharma LLC
Cardior Pharmaceuticals GmbH
Celltrion Inc
Cytokinetics Inc
DiNAQOR AG
Edgewise Therapeutics Inc
Genome Biologics UG
Haya Therapeutics SA
Igia Pharmaceuticals Inc
Imbria Pharmaceuticals Inc
Invivosciences Inc
Jaan Biotherapeutics LLC
Lead Discovery Center GmbH
LEXEO Therapeutics LLC
Novartis AG
Saliogen Therapeutics Inc
Tenaya Therapeutics Inc
Toa Eiyo Ltd
Hypertrophic Cardiomyopathy - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
History of Events
8-MI - Drug Profile
Product Description
Mechanism Of Action
aficamten - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDR-348T - Drug Profile
Product Description
Mechanism Of Action
CDR-641L - Drug Profile
Product Description
Mechanism Of Action
CK-271 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTG-20 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dasatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
DINA-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DINA-008 - Drug Profile
Product Description
Mechanism Of Action
DINA-009 - Drug Profile
Product Description
Mechanism Of Action
DINA-010 - Drug Profile
Product Description
Mechanism Of Action
DINA-011 - Drug Profile
Product Description
Mechanism Of Action
Drugs to Inhibit PDE3A1 for Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
EDG-002 - Drug Profile
Product Description
Mechanism Of Action
GEN-387 - Drug Profile
Product Description
Mechanism Of Action
Gene therapy for Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
GRK5 - Drug Profile
Product Description
Mechanism Of Action
HTX-001 - Drug Profile
Product Description
Mechanism Of Action
Hypertrophy Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
JN-210 - Drug Profile
Product Description
Mechanism Of Action
LX-2022 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mavacamten - Drug Profile
Product Description
Mechanism Of Action
History of Events
MYK-224 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MYK-581 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ninerafaxstat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Peptides to Agonize MFN2 for Charcot Marie Tooth Disease Type IIA and Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Cardiac Hypertrophy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
TN-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRPC6 ANTAGONIST - Drug Profile
Product Description
Mechanism Of Action
History of Events
TY-0305 - Drug Profile
Product Description
Mechanism Of Action
Hypertrophic Cardiomyopathy - Dormant Projects
Hypertrophic Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Aug 10, 2022: LianBio completes enrollment in pivotal phase 3 EXPLORER-CN trial of mavacamten in Chinese obstructive hypertrophic cardiomyopathy patients
Jun 13, 2022: Cytokinetics announces additional data from REDWOOD-HCM presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Jun 13, 2022: Cytokinetics announces additional results from REDWOOD-HCM to be presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
May 23, 2022: Cytokinetics announces data from REDWOOD-HCM OLE presented as late breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 09, 2022: LianBio Completes phase 1 pharmacokinetic study of mavacamten in Healthy Chinese Volunteers
Apr 29, 2022: BMS receives US FDA approval for Camzyos to treat cardiomyopathy
Apr 04, 2022: BMS’ mavacamten boosts cardiovascular outcomes in obstructive HCM study
Apr 02, 2022: Mavacamten demonstrated significant reduction in need for septal reduction therapy in symptomatic obstructive HCM patients in phase 3 VALOR trial
Apr 02, 2022: Cytokinetics announces results from cohort 3 of Redwood-HCM presented at American College of Cardiology 71st Annual Scientific Session
Mar 24, 2022: Cytokinetics announces presentations on aficamten at the American College of Cardiology 71st Annual Scientific Session & Expo
Mar 21, 2022: Bristol Myers Squibb to demonstrate the strength of its growing cardiovascular portfolio at the American College of Cardiology’s 71st annual scientific session
Mar 02, 2022: Cytokinetics announces Cohort 4 of REDWOOD-HCM is open to enrollment
Feb 23, 2022: Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
Feb 16, 2022: Jixing announces receipt of breakthrough therapy designation for AFICAMTEN in CHINA
Feb 16, 2022: Bristol Myers Squibb announces positive topline results from phase 3 VALOR-HCM trial, evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypertrophic Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypertrophic Cardiomyopathy - Pipeline by Algomedix Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2022
Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, 2022
Hypertrophic Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2022
Hypertrophic Cardiomyopathy - Pipeline by Celltrion Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Cytokinetics Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by DiNAQOR AG, 2022
Hypertrophic Cardiomyopathy - Pipeline by Edgewise Therapeutics Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Genome Biologics UG, 2022
Hypertrophic Cardiomyopathy - Pipeline by Haya Therapeutics SA, 2022
Hypertrophic Cardiomyopathy - Pipeline by Igia Pharmaceuticals Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Imbria Pharmaceuticals Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Invivosciences Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Jaan Biotherapeutics LLC, 2022
Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, 2022
Hypertrophic Cardiomyopathy - Pipeline by LEXEO Therapeutics LLC, 2022
Hypertrophic Cardiomyopathy - Pipeline by Novartis AG, 2022
Hypertrophic Cardiomyopathy - Pipeline by Saliogen Therapeutics Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Tenaya Therapeutics Inc, 2022
Hypertrophic Cardiomyopathy - Pipeline by Toa Eiyo Ltd, 2022
Hypertrophic Cardiomyopathy - Dormant Projects, 2022
List of Figures
Number of Products under Development for Hypertrophic Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
